8-K: vTv Therapeutics Announces Investor Presentation Highlighting Cadisegliatin's Potential in Type 1 Diabetes Treatment

vTv Therapeutics presents an investor update focusing on Cadisegliatin, a potential first-in-class oral adjunct therapy for Type 1 Diabetes, with Phase 3 data expected in the second half of 2026.

Summary

• vTv Therapeutics is focused on developing Cadisegliatin, a liver-selective glucokinase activator, as an oral adjunct therapy for Type 1 Diabetes (T1D).
• The company highlights the significant unmet need in T1D, where approximately 1.6 million people in the US and 9.4 million globally struggle to achieve target blood glucose control.
• Cadisegliatin has shown promise in Phase 2 trials, demonstrating a reduction in hypoglycemic episodes and HbA1c levels.
• The Phase 3 CATT1 study, which resumed in the second quarter of 2025, is targeting an enrollment of 150 subjects and is expected to report topline data in the second half of 2026.
• The company received Breakthrough Therapy designation from the FDA and completed a $51 million PIPE financing in February 2024.

Sentiment

Score: 7

Explanation: The presentation is generally positive, highlighting the potential of Cadisegliatin and the unmet need in the T1D market. However, it also includes cautionary statements about the risks and uncertainties of drug development, preventing a higher score.

Positives

• Cadisegliatin has shown positive results in Phase 2 trials, including reduced hypoglycemia and improved HbA1c levels.
• The drug has been well-tolerated in clinical trials.
• The FDA granted Breakthrough Therapy designation to Cadisegliatin.
• The company has secured $51 million in PIPE financing.
• Cadisegliatin did not adversely impact lipids in people living with T1D.

Negatives

• The development of Cadisegliatin is still in the clinical trial phase, and there is no guarantee of regulatory approval.
• The Phase 3 trial is ongoing, and the results are not yet available.
• The presentation includes a cautionary note regarding forward-looking statements, highlighting the risks and uncertainties associated with drug development.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Clinical trial outcomes and regulatory approvals are uncertain.
• The company's financial performance and fund-raising activities may vary.
• There is no guarantee that pipeline candidates will receive health authority approval or become commercially available for the use(s) being investigated.

Future Outlook

The company anticipates topline data from the Phase 3 CATT1 study in the second half of 2026, which will be crucial for determining the future of Cadisegliatin as a potential treatment for Type 1 Diabetes.

Management Comments

• Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties.

Industry Context

The presentation highlights the significant unmet need in the Type 1 Diabetes market, where there are currently no FDA-approved oral adjunct therapies. Cadisegliatin aims to fill this gap by providing an oral option to improve glucose control and reduce hypoglycemic events.

Comparison to Industry Standards

• The presentation references the ADA Standard of Care 2025, indicating an awareness of and adherence to current clinical guidelines.
• The SimpliciT1 study is compared to other diabetes studies, such as the DCCT, to contextualize the results.
• The company is targeting similar endpoints to those outlined in the FDA draft guidance issued in 2023 on diabetes-related clinical trials.

Stakeholder Impact

• Positive impact on patients with Type 1 Diabetes if Cadisegliatin is approved.
• Potential benefits for shareholders through increased company value.
• Opportunity for healthcare professionals to offer a new treatment option.

Next Steps

• Complete the Phase 3 CATT1 study.
• Analyze and report topline data from the CATT1 study in the second half of 2026.
• Pursue regulatory approval for Cadisegliatin.
• Continue development of other pipeline candidates.

Key Dates

Keywords

Cadisegliatin, Type 1 Diabetes, T1D, Glucokinase Activator, Hypoglycemia, HbA1c, vTv Therapeutics, CATT1 Study, Oral Adjunct Therapy, Diabetes